What is the appropriate management for a 55-year-old male presenting with urinary frequency and urgency, negative urinary tract infection work‑up, bladder ultrasound showing left nephrolithiasis without hydronephrosis, an enlarged prostate gland, and PSA 1.42 ng/mL?

Management of Urinary Frequency and Urgency in a 55-Year-Old Male with Prostate Enlargement and Incidental Nephrolithiasis

Start this patient on an alpha-blocker (tamsulosin or alfuzosin) as first-line therapy for his bothersome lower urinary tract symptoms (LUTS) attributed to benign prostatic enlargement, while monitoring the asymptomatic kidney stone conservatively. 1

Primary Issue: Benign Prostatic Enlargement with LUTS

The clinical picture clearly indicates benign prostatic obstruction (BPO) as the primary driver of symptoms. The patient presents with classic storage symptoms (frequency and urgency), has documented prostate enlargement on imaging, and a reassuring PSA of 1.42 ng/mL (well below the 4.0 ng/mL threshold that would warrant biopsy consideration) 1, 2.

Initial Medical Management Algorithm

Step 1: Alpha-Blocker Monotherapy

• Initiate an alpha-adrenergic antagonist (tamsulosin, alfuzosin, or similar) immediately 1, 3
• These medications address the dynamic component of obstruction by relaxing smooth muscle tone in the prostate and bladder neck
• Expected symptom improvement of 3-10 points on the International Prostate Symptom Score (IPSS) 3
• Reassess at 4-12 weeks to evaluate response 1

Step 2: Consider Combination Therapy if Inadequate Response

• If prostate volume exceeds 30-40 mL on imaging, add a 5-alpha reductase inhibitor (finasteride or dutasteride) to the alpha-blocker 1, 3
• This combination reduces progression risk to less than 10% compared to 10-15% with monotherapy 3
• 5-ARIs require minimum 1-year treatment duration to demonstrate benefit 4
• This combination is particularly important given his age (55) and documented prostate enlargement, as it prevents disease progression including acute urinary retention

Step 3: Address Persistent Storage Symptoms

• If urgency and frequency persist despite alpha-blocker therapy, consider adding an antimuscarinic (trospium) or beta-3 agonist (mirabegron) 1, 5, 3
• These medications can reduce voiding frequency by 2-4 times per day 3
• The combination of alpha-blocker plus antimuscarinic is safe and effective for persistent storage symptoms 5

Secondary Issue: Left Nephrolithiasis Management

The kidney stone requires conservative management only at this time. 6

Stone Management Rationale

The patient has:

• No hydronephrosis (ruling out obstruction)
• No symptoms of renal colic (UTI ruled out, no pain mentioned)
• No signs of infection or sepsis

According to the 2025 EAU urolithiasis guidelines, asymptomatic stones without obstruction do not require immediate intervention 6. The stone is incidental and unrelated to his presenting LUTS.

When to Intervene for the Stone

Intervention would only be indicated if the patient develops:

• Renal colic (treat with NSAIDs as first-line: diclofenac, ibuprofen, or metamizole) 6
• Signs of obstruction with hydronephrosis
• Sepsis (requiring urgent decompression via nephrostomy or ureteral stenting) 6
• Stone migration to ureter >5mm (consider medical expulsive therapy with alpha-blockers) 6

Important note: The alpha-blocker prescribed for BPO may actually provide dual benefit if the stone migrates to the ureter, as alpha-blockers are used for medical expulsive therapy 6.

Follow-Up Strategy

4-12 Week Reassessment:

• Repeat IPSS questionnaire to quantify symptom improvement
• Measure post-void residual (PVR) and perform uroflowmetry 1
• If symptoms improve and patient is satisfied, continue annual follow-up
• If inadequate response or intolerable side effects, escalate to combination therapy or refer to urology 1

Annual Monitoring:

• Repeat initial evaluation including symptom assessment
• Monitor for disease progression or complications (acute retention, recurrent UTI, hematuria)
• PSA monitoring is not routinely needed given his low baseline value, unless considering surgical intervention 1, 7

Stone Surveillance:

• Repeat imaging only if patient develops symptoms suggestive of stone movement or obstruction
• No routine surveillance imaging needed for asymptomatic stones without hydronephrosis 6

Critical Pitfalls to Avoid

1. Do not treat the kidney stone unless it becomes symptomatic - the LUTS are clearly prostatic in origin, not from the stone
2. Do not delay alpha-blocker therapy - this is the most effective first-line treatment with rapid onset (2-4 weeks) 1
3. Do not prescribe 5-ARI monotherapy initially - these take 3-6 months to show benefit and are less effective than alpha-blockers for immediate symptom relief 1
4. Do not refer to urology immediately - medical management should be attempted first unless complications are present 1, 8
5. Do not perform cystoscopy or pressure-flow studies - these are not indicated in straightforward BPO without complications 8, 7

Indications for Urology Referral

Refer if patient develops:

• Persistent symptoms despite optimal medical therapy
• Acute urinary retention
• Recurrent UTIs
• Gross hematuria
• Bladder stones
• Renal insufficiency from obstruction
• PVR >100-150 mL with bothersome symptoms 1, 8